[EN] METALLOENZYME INHIBITOR COMPOUNDS<br/>[FR] COMPOSÉS INHIBITEURS DE MÉTALLOENZYMES
申请人:VPS 3 INC
公开号:WO2018165520A1
公开(公告)日:2018-09-13
Provided are compounds having HDAC6 modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by HDAC6.
提供具有HDAC6调节活性的化合物,以及通过HDAC6介导的治疗疾病、疾病或症状的方法。
[EN] HETEROAROMATIC DERIVATIVES AND PHARMACEUTICAL APPLICATIONS THEREOF<br/>[FR] DÉRIVÉS HÉTÉROAROMATIQUES ET LEURS APPLICATIONS PHARMACEUTIQUES
申请人:SUNSHINE LAKE PHARMA CO LTD
公开号:WO2015161830A1
公开(公告)日:2015-10-29
Provided herein are novel heteroaromatic derivatives, or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a prodrug, a pharmaceutically acceptable salt or a prodrug thereof, and pharmaceutical compositions containing such compounds. Also provided herein are uses of such compounds or pharmaceutical compositions thereof in the manufacture of a medicament for treating respiratory diseases, especially chronic obstructive pulmonary disease (COPD).
[EN] PYRAZOLO [1,5-a] PYRIMIDINES USEFUL AS JAK2 INHIBITORS<br/>[FR] PYRAZOLO[1,5-A]PYRIMIDINES UTILES EN TANT QU'INHIBITEURS DE JAK2
申请人:VERTEX PHARMA
公开号:WO2009085913A1
公开(公告)日:2009-07-09
The present invention relates to compounds of formula (I) useful as selective inhibitors of JAK2 kinase. The invention also provides pharmaceutical acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various diseases, conditions or disorders. The invention also provides processes for preparing the compounds of the invention.
[EN] POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE<br/>[FR] COMPOSÉS DE CARBAMOYLPYRIDONE POLYCYCLIQUES ET LEUR UTILISATION PHARMACEUTIQUE
申请人:GILEAD SCIENCES INC
公开号:WO2014100323A1
公开(公告)日:2014-06-26
Compounds for use in the treatment of human immunodeficiency virus (HIV) infection are disclosed. The compounds have the following Formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, X, W, Y1, Y2, Ζ1 and Z4 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.